We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

27 hedge funds and large institutions have $14.1M invested in Marker Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,600% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 1

1,142% more capital invested

Capital invested by funds: $1.14M → $14.1M (+$13M)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

145% more funds holding

Funds holding: 11 → 27 (+16)

0.85% more ownership

Funds ownership: 0.32% → 1.17% (+0.85%)

Holders
27
Holders Change
+16
Holders Change %
+145.45%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$1.7M
2
CH
CVI Holdings
Delaware
+$1.27M
3
6CM
683 Capital Management
New York
+$1.02M
4
RI
RTW Investments
New York
+$1.02M
5
CC
Caxton Corporation
New Jersey
+$432K

Top Sellers

Rank Fund Capital Flow
1
NRS
Neville Rodie & Shaw
New York
-$469K
2
BFM
Boston Financial Management
Massachusetts
-$206K
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
1
Driehaus Capital Management
Illinois
$3.14M +$1.7M +33,309 New
CH
2
CVI Holdings
Delaware
$2.36M +$1.27M +25,000 New
6CM
3
683 Capital Management
New York
$1.89M +$1.02M +20,000 New
RI
4
RTW Investments
New York
$1.89M +$1.02M +20,000 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.77M +$259K +5,080 +37%
CC
6
Caxton Corporation
New Jersey
$798K +$432K +8,467 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$409K +$221K +4,343 New
MA
8
MYDA Advisors
New York
$375K +$203K +3,980 New
NRS
9
Neville Rodie & Shaw
New York
$284K -$469K -9,200 -75%
Northern Trust
10
Northern Trust
Illinois
$197K +$106K +2,083 New
State Street
11
State Street
Massachusetts
$191K +$104K +2,030 New
BlackRock
12
BlackRock
New York
$189K +$31.1K +609 +43%
RAM
13
Riggs Asset Management
Pennsylvania
$177K +$95.5K +1,873 New
AWP
14
Ascent Wealth Partners
New York
$97K +$52.4K +1,027 New
DLHL
15
Donald L. Hagan LLC
Florida
$94K +$51K +1,000 New
Barclays
16
Barclays
United Kingdom
$75K +$40.8K +800 New
UBS Group
17
UBS Group
Switzerland
$57K +$16.2K +317 +113%
US Bancorp
18
US Bancorp
Minnesota
$47K +$25.5K +500 New
Morgan Stanley
19
Morgan Stanley
New York
$38K +$19.2K +377 +1,450%
FIA
20
FNY Investment Advisers
New York
$23K +$12.7K +250 New
TDC
21
Thompson Davis & Co
Virginia
$15K +$8.31K +163 New
HNB
22
Huntington National Bank
Ohio
$5K – – –
NSIM
23
North Star Investment Management
Illinois
$4K – – –
JCM
24
Jacobi Capital Management
Pennsylvania
$4K +$2.04K +40 New
AG
25
Advisor Group
Arizona
$3K – – –
1
2

MRKR Hedge Fund Activity: Q2 2018 in Review

27 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2018, worth a combined $14.1M — up 1,142% from $1.14M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MRKR positions and 1 closed out — a net gain of 16 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.7M. The largest seller was Neville Rodie & Shaw, cutting an estimated $469K.

  • 27 institutional investors held Marker Therapeutics (MRKR) as of Q2 2018, up from 11 in Q1 2018.
  • Funds reported $14.1M of Marker Therapeutics stock for Q2 2018, up 1,142% quarter-over-quarter.
  • 17 funds opened new Marker Therapeutics positions in Q2 2018 and 1 closed out, a net change of +16 holders.
  • The largest Marker Therapeutics buyer in Q2 2018 was Driehaus Capital Management, an estimated $1.7M added.
  • The largest Marker Therapeutics seller in Q2 2018 was Neville Rodie & Shaw, an estimated $469K sold.

Based on aggregated 13F filings for Q2 2018.